

Seroprevalence of Immunoglobulin-G and of Immunoglobulin-M Anti-*Toxoplasma gondii* Antibodies in Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia

Hailuel Alem^{1*}, Getachew Tilahun², Daniel Fekade³ Nega Berhe² and Girmay Medhin²

¹College of Veterinary Medicine, Mekelle University, Mekele, Ethiopia

²Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia

³Department of Internal Medicine, School of Medicine, Addis Ababa University, Ethiopia

Abstract

Background: In Ethiopia, only a few studies on the seroprevalence of toxoplasmosis have been carried out among HIV/AIDS patients. The objective of this study was to determine the seroprevalence of toxoplasmosis among HIV/AIDS patients at Tikur Anbessa Specialized Hospital, Ethiopia, and to determine risk factors associated with seroprevalence.

Methods: Blood samples were collected from randomly selected 150 HIV-positive patients and IgM and IgG anti-toxoplasma antibodies were quantified by using Enzyme immunoassay technique (HUMAN-ELISA, GERMANY). Ethical approval for the study was obtained from the Institutional Review Board of the Faculty of Medicine, Addis Ababa University. Questionnaire was administered to assess the risk factors associated with the prevalence of toxoplasmosis in HIV patients.

Results: Of the one hundred fifty patients 108 (72%) were females and 42 (28%) were males. The mean (sd) age was 38.4 (9.5). Based on IgG anti-Toxoplasma antibodies status, the seroprevalence of toxoplasmosis in HIV-positive patients was 94%. No IgM antibody was detected. Consumption of raw vegetables and not having primary information about toxoplasmosis were significant association with the presence of anti-Toxoplasma antibody ($p < 0.05$). Inexact logistic regression analysis consumption of raw vegetable (adjusted OR=7.49, 95% CI 1.29-58.93) was significant risk factor for toxoplasmosis and having information about toxoplasmosis (adjusted OR=.083, 95% CI .011-.499) had significant protective effect. The mean (sd) CD4 count was 341.1 (173.6) cells/ μ L. The association between the presence of anti-toxoplasma antibody and CD4+ T lymphocyte cells count was not statistically significant.

Conclusions: The findings showed that there is a high prevalence of chronic toxoplasmosis in HIV/AIDS patients and the risk factors were consumption of raw vegetable and lack of information about toxoplasmosis. Therefore, routine screening for *Toxoplasma* should be undertaken for all HIV-infected patients. Moreover, creating awareness about toxoplasmosis and its risk factors should be prioritized.

Keywords: Anti-Toxoplasma antibodies; HIV/AIDS; Prevalence; Risk factors; Toxoplasmosis

Background

Toxoplasmosis is caused by infection with the obligate, intracellular parasite, *Toxoplasma gondii* [1]. It readily infects human beings and clinical illness is relatively uncommon [2]. *Toxoplasma gondii* is estimated to affect around two billion people worldwide, and it has gradually evolved over the past decades to be among the most common opportunistic diseases in Human Immunodeficiency Virus infection/Acquired Immunodeficiency Syndrome (HIV/AIDS) in developing countries [3]. Transmission of the disease mainly occur through ingestion of tissue cysts in raw and undercooked meat, exposure to oocysts in contaminated vegetable or contact with faeces of a felid. In Ethiopia, general prevalence is about 80% in the adult population [2], and 93.3% among HIV-infected patients seeking either HIV or immunological testing at St. Paul's Hospital, Addis Ababa, Ethiopia [4]. Disease due to infection with the protozoan parasite, *Toxoplasma gondii*, is a major complication of HIV-induced immunosuppression [5], and responsible for congenital infections and abortion in immunocompetent individuals and opportunistic infections in immunodeficient individuals [1]. Toxoplasmosis in patients with AIDS is usually the result of reactivation of latent infection. Toxoplasmosis among Acquired Immunodeficiency Syndrome (AIDS) patients manifests primarily as a life threatening condition, toxoplasmic encephalitis (TE) [4]. Toxoplasmic encephalitis usually occurs in HIV-infected patients with CD4+ T- cell counts $< 100/\mu$ L [6]. In Ethiopia only a few studies on the seroprevalence of toxoplasmosis have

been carried out among HIV/AIDS patients. The objective of this study was to determine the seroprevalence of toxoplasmosis among HIV/AIDS patients at Tikur Anbessa Specialized Hospital and to determine risk factors associated with seropositivity.

Methods

Description of the study design and setting

A cross-sectional study was carried out from October, 2011-February, 2012 at Tikur Anbessa Specialized Hospital at Provider Initiated Testing and Counseling (PITC) sub unit under the Infectious Disease Unit to determine the prevalence of toxoplasmosis in HIV/AIDS patients visiting the hospital. Tikur Anbessa Specialized Hospital, which is located in Lideta sub city in Addis Ababa,

***Corresponding author:** Hailuel Alemu, College of Veterinary Medicine, Mekelle University, Mekele, Ethiopia, E-mail: leule@rocketmail.com

Received September 05, 2013; **Accepted** October 26, 2013; **Published** November 01, 2013

Citation: Alemu H, Tilahun G, Fekade D, Berhe N, Medhin G (2013) Seroprevalence of Immunoglobulin-G and of Immunoglobulin-M Anti-*Toxoplasma gondii* Antibodies in Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. J Infect Dis Ther 1: 119. doi:10.4172/2332-0877.1000119

Copyright: © 2013 Alemu H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

the hospital works under Addis Ababa University. It provides multidisciplinary clinical service for all patients who come from different parts of the country and the Hospital started antiretroviral treatment service, since March 2005.

Recruitment of study participants

150 HIV/AIDS patients were randomly selected from the provider initiated testing and counseling (PITC) unit to participate in the study and eight individuals were not volunteer to participate in the study. Using simple random sampling technique, patient's history card was selected in the morning and afternoon for twenty consecutive working days. Moreover, on average twenty one patients visited PITC unit daily during the study period.

Ethical consideration

Ethical approval for the study was obtained from the Institutional Review Board of the Faculty of Medicine, Addis Ababa University (Ref. No. 079/11/Ext.). After obtaining written/verbal consent from 150 randomly selected HIV/AIDS patients, relevant information was obtained using a questionnaire. Moreover, 5 ml of venous blood was collected from each patient and the collected sera were kept at -20°C, until use.

Sample analysis

IgM and IgG antibodies to *Toxoplasma gondii* from serum samples were quantified by an Enzyme immunoassay technique, according to the manufacturer's instructions (HUMAN- ELISA, GERMANY) and CD4+ T lymphocyte cell counts less than a month's period were taken from registration book of Tikur Anbessa Specialized Hospital.

Data management and analysis

Data obtained from questionnaire and laboratory tests were

entered using Microsoft Excel 2010, and analysis was carried out using STATA version 11 software and SPSS version 20. The Fisher's exact test was used for testing the association between possible risk factors and disease transmission, also for the association between CD4+ T lymphocyte cell counts and *Toxoplasma* seropositivity. The Alpha (α) value, allowance for type one error, was set at 0.05, and therefore, a p-value of less than 0.05 was regarded as statistically significant to reject the null hypothesis. Odds ratio and corresponding 95% Confidence Interval (CI) were used to quantify the degree of associated with different variables. The relative contribution of each selected variables to the outcome of interest were also assessed using exact logistic regression model.

Results

Socio-demographic characteristics

The selected 150 study subjects were included in the questionnaire survey and different socio demographic characteristics were considered for the study (Table 1).

Risk factors associated with seroprevalence of *Toxoplasma gondii*

Results from bivariate analysis: Risk factors associated with the seroprevalence of *Toxoplasma gondii* like living with cat, consumption of uncooked meat and raw vegetables and primary information about toxoplasmosis were assessed. Of these, primary information about toxoplasmosis ($P < 0.05$) and consumption of raw vegetable ($P < 0.05$) were significantly associated with the seroprevalence of the disease (Table 2).

Results from exact logistic regression: Different risk factors were assessed before and after adjusting seemingly significant predictor in the exact logistic regression model. The like hood of experiencing

Socio demographic Characteristics		IgG antibody				
		Total N	Positive N (%)	Fisher's Exact	Crude odds ratio (95% CI)	p-value
Age	11-20	2	2 (100%)	0.912	1.213 (.593- 2.743)	0.729
	21-30	36	34 (94.4)			
	31-40	67	62 (92.5)			
	41-50	26	24 (92.3)			
	51-60	16	16 (100%)			
	61-70	3	3 (100%)			
Sex	Female	108	100 (92.6)	0.446	3.26 (.414 -149)	0.450
	Male	42	41 (97.6)			
Marital status	Married	126	118 (93.7)	0.189	392 (.077- 2.60)	0.377
	single	24	23 (95.8)			
Level of education	Illiterate	29	27 (19.15)	0.115	2.30 (.921-7.60)	0.080
	Primary education	64	60 (42.55)			
	Secondary education and above	57	54 (38.30)			
Religion	Orthodox	130	123 (94.6)	0.343	620 (.253- 1.97)	0.4309
	Muslim	6	6 (100)			
	Protestant	14	12 (85.7)			
Income (in Birr)	<300	76	71 (93.4)	0.746	1.49 (.580- 4.64)	0.518
	300-600	39	37 (94.9)			
	>600	35	33 (94.3)			
Highly Active Antiretroviral Therapy (HAAR)	With HAART	144	136 (94.4)	1.000	298 (.027-15.63)	0.629
	Without HAART	6	5 (83.3)			

Table 1: Socio-demographic characteristics of HIV/AIDS patients with and without Toxoplasma infection using Fisher's exact and exact logistic regression model.

Risk factors	IgG antibody		
	Total N	Positive N (%)	Fishers exact
Contact ownership			
Yes	61	57 (93.4)	1.000
No	87	84 (96.6)	
Consumption of uncooked meat			
Yes	83	77 (92.3)	0.732
No	67	64 (95.5)	
Consumption of raw vegetables			
Yes	102	99 (97.1)	0.030
No	48	42 (87.5)	
Primary information about toxoplasmosis			
Yes	21	16 (76.2)	0.0030
No	129	125 (96.9)	

Table 2: Seroprevalence of toxoplasmosis in relation to various possible risk factors in HIV/AIDS Patients using Fisher's exact test.

Characteristics	Crude odds ratio (COR) (95% Confidence Interval)		Adjusted odds ratio (AOR) (95% Confidence Interval)	p-value	
Cat ownership	Yes	1.17 (.223-5.73)	1.000	574 (.079- 3.35)	0.747
	No	1.00			
Consumption of uncooked meat	Yes	1.65 (.337-10.64)	0.729	2.36 (.387-18.97)	0.487
	No	1.00			
Consumption of raw vegetables	Yes	4.65 (.942-30.14)	0.060	7.91 (1.29-65.82)	0.021
	No	1.00			
Primary information about toxoplasmosis	Yes	105 (.018- .542)	0.005	083 (.011-.499)	0.004
	No	1.00			

Table 3: Exact logistic regression analysis on seemingly significant predictors of *T. gondii* infection.

CD4 count (cells/ μ L)	IgG Antibody		
	Total N	Positive N(%)	Fishers exact
<200	33	30 (90.9)	0.089
200-500	94	91(96.8)	
>500	23	20 (86.9)	

Table 4: Status of antibodies to *Toxoplasma gondii* based on different ranges of CD4+ T cell counts.

Toxoplasma gondii antibodies in their serum was higher among HIV/AIDS patients who consumed raw vegetables, and the prevalence of *T. gondii* was lower among study participants who did have information about toxoplasmosis. Moreover, consumption of raw vegetable (adjusted OR=7.49, 95%CI 1.29-58.93) was significant risk factor for toxoplasmosis and having information about toxoplasmosis (adjusted OR=.083, 95%CI .011- .499) had significant protective effect (Table 3).

Laboratory results

ELISA results were interpreted as IgM and IgG positive and negative in terms of absorbance (optic density). A total of 150 immune compromised (HIV/AIDS) patients participated in this sero-survey. 141 (94%) of the patients were sero-positive anti-*Toxoplasma gondii* IgG antibodies, whereas anti-*Toxoplasma gondii* IgM antibodies were not detected in patients' serum. There was no statistically significant association between CD4+ T lymphocyte cells count and anti-*Toxoplasma gondii* IgG antibodies found ($P>0.05$) (Table 4).

Discussion

In the current study, the seroprevalence of *Toxoplasma gondii* showed 94% in HIV/AIDS patients, as measured by serum antibody

level of IgG, which is comparable with previous study in the same study area, *Toxoplasma* infection in Addis Ababa was observed with prevalence of 93.3% [4]. The seroprevalence of *Toxoplasma gondii* in HIV/AIDS patients in this study differ much from that obtained in other countries: 75.4% in Nigeria, 60% from Cote d'Ivoire, 58.4% in Tunisia, 53.6% in Benin, 40.2% in Senegal [7], and 54% prevalence in HIV positive adults in Uganda (3), 41.2% in HIV/AIDS patients in Malaysia [8]. These variations may be due to difference in geographical area and living condition.

In agreement with the current study, the seroprevalence of *Toxoplasma gondii* estimated for human population varies greatly among different countries, among different geographical areas within the same country, and among different ethnic groups living in the same area [9]. The differences in seropositivities are based on several factors like the geographical distribution of the study sites and socioeconomic status [8].

Recent acquired *Toxoplasma gondii* infection is usually based on the detection of specific IgM antibody. In the current study, no anti-*Toxoplasma gondii* IgM antibodies were detected. In agreement with other similar studies: 1% in Iran [10], 0% in Mexico [11] and 0% in

India [12]. CD4+ T lymphocyte cell count is one of the prognostic marker in HIV/AIDS patients, in this study, there was no statistical significant association between CD4 at different ranges of CD4 cells/ μ L (<200, 200-500 and >500) and *Toxoplasma* infection. In agreement with the current study, there was no significance association between CD4 count <200 VS >200 [13]. The majority of the studied population was on antiretroviral treatment regimens. Recently, Highly Active Antiretroviral Therapy (HAART) against HIV infection has been advocated for improving the immune status of patients, thus reducing the incidence of opportunistic infections [14]. With the widespread use of HAART, the incidence of Central Nervous System (CNS) toxoplasmosis has decreased [15], and between 97% and 100% of HIV infected patients with *Toxoplasma* encephalitis have anti-*Toxoplasma gondii* IgG antibodies [16], and low CD4 cell count is a significant factor contributing to the occurrence of active toxoplasmosis in patients with AIDS [17].

Socio demographic characteristics were not significantly associated with the seroprevalence of *Toxoplasma gondii*. Similarly, studies in India demonstrated that there is no association between the prevalence of toxoplasmosis and demographic and baseline characteristics [12]. No significant relationship was observed between seroprevalence of toxoplasmosis and socio-demographic and baseline characteristics of the patients, the HIV transmission risk factors and the CD4 counts [10].

The current study also showed the likelihood of experiencing *Toxoplasma gondii* antibodies in their serum was significantly higher in patients who consumed raw vegetables and who did not have sufficient information about toxoplasmosis. This is probably due to the living condition and the dietary habit of the people. In Ethiopia, eating raw vegetable is common and treatment of it before eating is uncommon. Increasing the age, raw or half-cooked meat use, keeping cat in house and living in warm, humid and low-revenue places increases the prevalence of toxoplasmosis [18]. In Mexico and Brazil, cats are fed with raw viscera and leftover, increasing the chance of human infection [14].

High seroprevalence of chronic *Toxoplasma* infection among the study population seems reasonable as raw or insufficiently cooked meat prepared in a various favorite cultural food is consumed. In addition, cats are abundant to cause environmental contamination and the climate is favorable to favor survival of the parasite [4]. Cultural values have great impact on the prevalence of a disease, in our culture cats are always in close proximity to the people. One of the causes for this high prevalence is attributed to the close contact of humans with cats [19].

This study showed chronic toxoplasmosis was high in HIV/AIDS patients. Socio-demographic characteristics and different risk factors were also assessed in association with the incidence of toxoplasmosis. Hence, *Toxoplasma gondii* has emerged as an important opportunistic infection in HIV/AIDS patients. So, HIV/AIDS patients should be screened for anti-*Toxoplasma* antibodies and public awareness about the infection should be prioritized.

Competing Interests

The author(s) declare that they have no competing interests.

Author's Contributions

Getachew Tilahun, Daniel Fekade and Nega Berhe conceived of the study, and participated in its design and coordination and helped to draft the manuscript.

Hailuel Alemu carried out the serological studies and drafted the manuscript.

Girmay Medhin participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.

Author's Information

On behalf of the authors, I take the full responsibility for the article during submission and peer review.

Acknowledgement

The authors would like to thank the Addis Ababa University for funding and all staff of Tikur Anbessa Specialized Hospital and the PICT Unit, for their assistance during data and sample collection and the Armauer Hansen Research Institute during laboratory work.

References

1. Unno A, Kitoh K, Takashima Y (2010) Up-regulation of hyaluronan receptors in *Toxoplasma gondii*-infected monocytic cells. *Biochem Biophys Res Commun* 391: 477-480.
2. Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health (FHAPCO) (2007) Guidelines for management of opportunistic infections and anti-retroviral treatment in adolescents and adults in Ethiopia. 19-21.
3. Lindström I, Kaddu-Mulindwa DH, Kironde F, Lindh J (2006) Prevalence of latent and reactivated *Toxoplasma gondii* parasites in HIV-patients from Uganda. *Acta Trop* 100: 218-222.
4. Shimelis T, Tebeje M, Tadesse E, Tegbaru B, Terefe A (2009) Sero-prevalence of latent *Toxoplasma gondii* infection among HIV-infected and HIV-uninfected people in Addis Ababa, Ethiopia: A comparative cross-sectional study. *BMC Res Notes* 2: 213.
5. Djurkovic-Djakovic O, Bobic B, Vukovic D, Marinkovic, J, Jevtic D (1997) Risk for Toxoplasmic encephalitis in AIDS patients in Yugoslavia. *Int J Infect Dis* 2: 74-78.
6. Laing RB, Flegg PJ, Brettell RP, Leen CL, Burns SM (1996) Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. *Int J STD AIDS* 7: 258-264.
7. Jules C, Assob A, Njunda S, Nsagha H, Kamga E, et al. (2011) *Toxoplasma* antibodies amongst HIV/AIDS patients attending The University Teaching Hospital Yaounde, In Cameroon. *Afri J Clin Exp Microbiol* 12: 119-123.
8. Nissapatorn V, Lee C, Cho SM, Rohela M, Anuar K, et al. (2003) Toxoplasmosis in HIV/AIDS patients in Malaysia. *Med J Malaysia* 34: 80-85.
9. Sempore J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, et al. (2006) *Toxoplasma gondii*, HCV, and HBV seroprevalence and co-infection among HIV-positive and -negative pregnant women in Burkina Faso. *J Med Virol* 78: 730-733.
10. Mohraz M, Mehrkhani F, Jam S, Seyed Alinaghi S, Sabzvari, D et al. (2011) Seroprevalence of Toxoplasmosis in HIV+/AIDS Patients in Iran. *Acta Medica Iranica* 49: 213-218.
11. Meisheri YV, Mehta S, Patel U (1997) A prospective study of seroprevalence of Toxoplasmosis in general population, and in HIV/AIDS patients in Bombay, India. *J Postgrad Med* 43: 93-97.
12. Galván Ramírez ML, Valdez Alvarado V, Vargas Gutierrez G, Jiménez González O, García Cosío C, et al. (1997) Prevalence of IgG and IgM anti-*Toxoplasma* antibodies in patients with HIV and acquired immunodeficiency syndrome (AIDS). *Rev Soc Bras Med Trop* 30: 465-467.
13. Nissapatorn V, Kamarulzaman A, Init I, Tan LH, Rohela M, et al. (2002) Seroepidemiology of toxoplasmosis among HIV-infected patients and healthy blood donors. *Med J Malaysia* 57: 304-310.
14. Sukthana Y, Chintana T, Supathanapong W, Siripanth C, Lekkla A (2000) Prevalence of toxoplasmosis in selected populations in Thailand. *J Trop Med Parasitol* 23: 53-58.
15. Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV (2001) Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. *Clin Infect Dis* 33: 1747-1755.

16. Luft BJ, Brooks RG, Conley FK, McCabe RE, Remington JS (1984) Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 252: 913-917.
17. Davarpanah MA, Mehrabani D, Neirami R, Ghahremanpoori M, Darvishi M (2007) Toxoplasmosis in HIV/AIDS patients in Shiraz, Southern Iran. Iranian Red Crescent Med J: 9: 22-27.
18. Youssefi MR, Sefidgar AA, Mostafazadeh A, Omran SM (2007) Serologic evaluation of toxoplasmosis in matrimonial women in Babol, Iran. Pak J Biol Sci 10: 1550-1552.
19. Negash T, Tilahun G, Medhin G (2008) Seroprevalence of *Toxoplasma gondii* in Nazaret town, Ethiopia. East Afr J Public Health 5: 211-214.

Citation: Aleme H, Tilahun G, Fekade D, Berhe N, Medhin G (2013) Sereoprevalence of Immunoglobulin-G and of Immunoglobulin-M *Anti-Toxoplasma gondii* Antibodies in Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. J Infect Dis Ther 1: 119. doi:[10.4172/2332-0877.1000119](https://doi.org/10.4172/2332-0877.1000119)

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 300 Open Access Journals
- 25,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission/>